Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia

A method for decreasing the dose of an anemia medicament, comprising:

• administering to a subject having anemia or at risk of developing anemia an anemia medicament in a sub-therapeutic dosage and an immunostimulatory nucleic acid, wherein the anemia medicament in a sub-therapeutic dosage and the immunostimulatory nucleic acid are effective to treat or prevent anemia in the subject.

A method for treating or preventing anemia, comprising:

• administering to a subject having anemia or at risk of developing anemia an immunostimulatory nucleic acid selected from the group consisting of a methylated CpG nucleic acid, a T-rich nucleic acid, a poly-G nucleic acid, a nucleic acid having a phosphorothioate backbone, and any combination thereof, wherein the nucleic acid having a phosphorothioate backbone is not a CpG nucleic acid, in an effective amount to treat or prevent the anemia.

A method for treating or preventing thrombocytopenia, comprising:

• administering to a subject having thrombocytopenia or at risk of developing thrombocytopenia a combination of an immunostimulatory nucleic acid and a thrombocytopenia medicament in an effective amount to treat or prevent the thrombocytopenia.

A method for decreasing the dose of a thrombocytopenia medicament, comprising:

• administering to a subject having thrombocytopenia or at risk of developing thrombocytopenia a thrombocytopenia medicament in a sub-therapeutic dosage and an immunostimulatory nucleic acid, wherein the thrombocytopenia medicament in a sub-therapeutic dosage and the immunostimulatory nucleic acid are effective to treat or prevent thrombocytopenia in the subject.

A method for treating or preventing thrombocytopenia, comprising:

• administering to a subject having thrombocytopenia or at risk of developing thrombocytopenia an immunostimulatory nucleic acid selected from the group consisting of a methylated CpG nucleic acid, a T-rich nucleic acid, a poly-G nucleic acid, a nucleic acid having a phosphorothioate backbone, and any combination thereof, wherein the nucleic acid having a phosphorothioate backbone is not a CpG nucleic acid, in an effective amount to treat or prevent the thrombocytopenia.

A method for treating or preventing neutropenia, comprising:

• administering to a subject having neutropenia or at risk of developing neutropenia a combination of an immunostimulatory nucleic acid and a neutropenia medicament in an effective amount to treat or prevent the neutropenia.

A method for increasing the dose of a neutropenia medicament, comprising:

• administering to a subject having neutropenia or at risk of developing neutropenia a medicament in a dose which ordinarily induces side effects, and
• administering to the subject an effective amount for preventing the induction of side effects by the neutropenia medicament of an immunostimulatory nucleic acid.

A method for decreasing the dose of a neutropenia medicament, comprising:

• administering to a subject having neutropenia or at risk of developing neutropenia a a neutropenia medicament in a sub-therapeutic dosage and an immunostimulatory nucleic acid, wherein the neutropenia medicament in a sub-therapeutic dosage and the immunostimulatory nucleic acid produce a therapeutic are effective to treat or prevent neutropenia in the subject.

A method for treating or preventing neutropenia, comprising:

• administering to a subject having neutropenia or at risk of developing neutropenia an immunostimulatory nucleic acid selected from the group consisting of a methylated CpG nucleic acid, a T-rich nucleic acid, a poly-G nucleic acid, a nucleic acid having a phosphorothioate backbone, and any combination thereof, wherein the nucleic acid having a phosphorothioate backbone is not a CpG nucleic acid, in an effective amount to treat or prevent the neutropenia.

A pharmaceutical composition, comprising:

• an immunostimulatory nucleic acid and an anemia medicament, formulated in a pharmaceutically acceptable carrier and in an effective amount for treating or preventing anemia.

A pharmaceutical composition, comprising:

• an immunostimulatory nucleic acid and a thrombocytopenia medicament, formulated in a pharmaceutically acceptable carrier and in an effective amount for treating or preventing thrombocytopenia.

A pharmaceutical composition, comprising:

• an immunostimulatory nucleic acid and a neutropenia medicament, formulated in a pharmaceutically acceptable carrier and in an effective amount for treating or preventing neutropenia.